现状与未来：肥胖症的药物治疗
Present and future: pharmacologic treatment of obesity.
作者信息
Glandt Mariela, Raz Itamar
机构信息
Department of Endocrinology, Bronx-Lebanon Hospital Center, Bronx, NY 10457, USA.
出版信息
J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.
Abstract
Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.
摘要
肥胖如今已成为我们这个时代最大的健康问题之一。饮食和运动对预防和治疗都最为有效；不幸的是，两者都需要很强的自律性且难以坚持。药物治疗是一种可能的辅助手段，但其效果有限，还受副作用限制，而且体重减轻仅在服药期间持续，因为一旦停止治疗，体重就会反弹。西布曲明是一种曾用于长期治疗的拟交感神经药物，它是因副作用而最近被撤出市场的最新药物；在这种情况下，其副作用是心血管事件风险增加。本文综述了可用于治疗肥胖的药物，包括许多最近已退出市场药物。此外，还讨论了目前正在研究的一些新治疗方法。
相似文献
1
Present and future: pharmacologic treatment of obesity.现状与未来：肥胖症的药物治疗
J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.
2
[The pharmacological treatment of obesity: past, present and future].[肥胖症的药物治疗：过去、现在与未来]
Orv Hetil. 2012 Mar 11;153(10):363-73. doi: 10.1556/OH.2012.29317.
3
[Pharmacological therapy of obesity].[肥胖症的药物治疗]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
4
Long-term effects of weight-reducing drugs in people with hypertension.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
5
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.肥胖治疗的长期效果、经济后果及其对健康改善影响的系统评价
Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210.
6
Long-term effects of weight-reducing drugs in hypertensive patients.减肥药物对高血压患者的长期影响。
Cochrane Database Syst Rev. 2013 Mar 28(3):CD007654. doi: 10.1002/14651858.CD007654.pub3.
8
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.在初级保健中使用药物治疗肥胖患者的临床效果和成本效益如何？系统评价。
Health Technol Assess. 2012;16(5):iii-xiv, 1-195. doi: 10.3310/hta16050.
9
Safety of antiobesity drugs.抗肥胖药物的安全性。
Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.
10
Modern medical management of obesity: the role of pharmaceutical intervention.肥胖症的现代医学管理：药物干预的作用。
J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. doi: 10.1016/s0002-8223(98)00706-8.
引用本文的文献
1
Metabolic Efficacy and Diabetes Remission Predictors Following 'Sleeve Gastrectomy with Loop Duodenojejunal Bypass' Surgery.“袖状胃切除术联合袢式十二指肠空肠旁路术”术后的代谢疗效及糖尿病缓解预测因素
J Metab Bariatr Surg. 2020 Dec;9(2):33-41. doi: 10.17476/jmbs.2020.9.2.33. Epub 2020 Dec 31.
2
Phytosterols: Nutritional Health Players in the Management of Obesity and Its Related Disorders.植物甾醇：肥胖及其相关疾病管理中的营养健康要素
Antioxidants (Basel). 2020 Dec 12;9(12):1266. doi: 10.3390/antiox9121266.
3
Relationship of estrogen synthesis capacity in the brain with obesity and self-control in men and women.大脑中雌激素合成能力与男性和女性肥胖和自我控制的关系。
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22962-22966. doi: 10.1073/pnas.2006117117. Epub 2020 Aug 31.
4
Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies.天然来源或合理设计的肽可用于超重、肥胖和 2 型糖尿病治疗。
Molecules. 2020 Feb 29;25(5):1093. doi: 10.3390/molecules25051093.
5
Inhibition of intestinal lipases alleviates the adverse effects caused by high-fat diet in Nile tilapia.抑制肠道脂肪酶可减轻高脂饮食对罗非鱼造成的不良影响。
Fish Physiol Biochem. 2020 Feb;46(1):111-123. doi: 10.1007/s10695-019-00701-x. Epub 2019 Sep 13.
6
(Yacon) Flour Improves Visceral Adiposity and Metabolic Parameters in High-Fat-Diet-Fed Rats.（雪莲果）面粉改善高脂饮食喂养大鼠的内脏脂肪过多及代谢参数。
J Obes. 2018 Oct 28;2018:5341384. doi: 10.1155/2018/5341384. eCollection 2018.
7
Germinated brown rice ameliorates obesity in high-fat diet induced obese rats.发芽糙米可改善高脂饮食诱导的肥胖大鼠的肥胖状况。
BMC Complement Altern Med. 2016 May 23;16:140. doi: 10.1186/s12906-016-1116-y.
8
Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial.补充二十二碳六烯酸在极低热量生酮饮食治疗肥胖中的作用：一项随机临床试验。
Endocrine. 2016 Oct;54(1):111-122. doi: 10.1007/s12020-016-0964-z. Epub 2016 Apr 27.
9
Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass.腹腔镜Roux-en-Y胃旁路术后短期糖尿病缓解的预测因素
Obes Surg. 2015 May;25(5):782-7. doi: 10.1007/s11695-014-1477-6.
10
Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity.极低热量生酮饮食与标准低热量饮食治疗肥胖症的比较。
Endocrine. 2014 Dec;47(3):793-805. doi: 10.1007/s12020-014-0192-3. Epub 2014 Mar 4.
本文引用的文献
1
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.西布曲明对超重和肥胖受试者心血管结局的影响。
N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114.
2
Gestational diabetes mellitus and obesity.妊娠期糖尿病与肥胖症。
Diabetes Care. 2010 May;33(5):e60-5. doi: 10.2337/dc10-zb05.
3
Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes.糖尿病患者体重管理的 LOOK AHEAD（糖尿病患者健康行动）临床试验中的心血管疾病危险因素、抑郁症状和抗抑郁药物使用。
Diabetologia. 2010 Aug;53(8):1581-9. doi: 10.1007/s00125-010-1765-1. Epub 2010 Apr 28.
4
Liraglutide (Victoza) for type 2 diabetes.利拉鲁肽（维达列汀）用于2型糖尿病。
Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.
5
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.在伴有和不伴有糖尿病前期的肥胖受试者中，艾塞那肽和生活方式改变对体重和葡萄糖耐量的影响。
Diabetes Care. 2010 Jun;33(6):1173-5. doi: 10.2337/dc09-1203. Epub 2010 Mar 23.
6
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.度拉糖肽每周一次治疗可在 52 周内持续控制血糖和减轻体重。
Diabetes Care. 2010 Jun;33(6):1255-61. doi: 10.2337/dc09-1914. Epub 2010 Mar 9.
7
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.在一项多中心试验中，普兰林肽与西布曲明或 phentermine 联合使用可增强减肥效果。
Obesity (Silver Spring). 2010 Sep;18(9):1739-46. doi: 10.1038/oby.2009.478. Epub 2010 Jan 21.
8
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.奥利司他和西布曲明治疗后血压的长期变化：一项荟萃分析。
Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x.
9
Effect of topiramate on acid-base balance: extent, mechanism and effects.托吡酯对酸碱平衡的影响：程度、机制和影响。
Br J Clin Pharmacol. 2009 Nov;68(5):655-61. doi: 10.1111/j.1365-2125.2009.03521.x.
10
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.利拉鲁肽治疗肥胖症的效果：一项随机、双盲、安慰剂对照研究。
Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23.
Zotero 插件